25 results match your criteria: "Makerere University Infectious Diseases Institute.[Affiliation]"

Background: Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development. We aimed to assess whether the effectiveness of the Bacillus Calmette-Guérin (BCG) vaccine for prevention of Mycobacterium tuberculosis infection was consistent with that for prevention of tuberculosis disease.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate blood glucose outcomes in people with HIV (PWH) who have pre-diabetes and are starting treatment with dolutegravir compared to those with normal glucose levels.
  • Researchers conducted a matched cohort study with 44 PWH with pre-diabetes and 88 with normal glucose, measuring changes in fasting and 2-hour blood glucose levels at various points over 48 weeks.
  • Results showed that while those with normal glucose experienced an increase in fasting blood glucose, those with pre-diabetes saw a significant decrease, indicating improvement in glucose metrics, questioning the need for intensive glucose monitoring in the initial months of dolutegravir treatment.
View Article and Find Full Text PDF

In this cohort study, we determined time to blood pressure (BP) control and its predictors among hypertensive PLHIV enrolled in integrated hypertension-HIV care based on the World Health Organization (WHO) HEARTS strategy at Mulago Immunosuppression Clinic in Uganda. From August 2019 to March 2020, we enrolled hypertensive PLHIV aged 18 years and initiated Amlodipine 5 mg mono-therapy for BP (140-159)/(90-99) mmHg or Amlodipine 5 mg/Valsartan 80 mg duo-therapy for BP ≥ 160/90 mmHg. Patients were followed with a treatment escalation plan until BP control, defined as BP < 140/90 mmHg.

View Article and Find Full Text PDF

Dolutegravir (DTG), an integrase strand transfer inhibitor is currently the recommended first and second line anti-retroviral therapy (ART) anchor agent by the World Health Organization due to its favorable side effect profile, high efficacy and genetic barrier to resistance.Despite its very good side effect profile, there have been multiple case reports of ART experienced patients developing hyperglycemia within weeks to a few months after switching to DTG preceded by weight loss. At population level, however, DTG as well as other integrase inhibitors have been demonstrated to have a reduced risk of incident diabetes mellitus (T2DM) compared to other HIV drug classes.

View Article and Find Full Text PDF

Background: The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with HIV (PWH) presenting with accelerated hyperglycemia after a few weeks to months of exposure to DTG. Having demonstrated a low incidence of diabetes mellitus and improving blood glucose trajectories in a cohort of ART naïve Ugandan PWH on DTG, we sought to determine whether the observed improvement in blood glucose did not mask background compensated insulin resistance.

View Article and Find Full Text PDF

Dolutegravir (DTG), an integrase strand transfer inhibitor is currently the recommended first and second line anti-retroviral therapy (ART) anchor agent by the World Health Organization. This followed widespread reports of primary resistance to non-nucleoside reverse transcriptase inhibitors. Despite its very good side effect profile, there have been multiple case reports of ART experienced patients developing hyperglycemia within weeks to a few months after switching to DTG preceded by weight loss.

View Article and Find Full Text PDF
Article Synopsis
  • The Uganda Ministry of Health recommends regular blood glucose monitoring for HIV patients with pre-diabetes starting dolutegravir.
  • In a study comparing 44 HIV patients with pre-diabetes to 88 with normal glucose levels, significant changes in fasting blood glucose after 48 weeks were observed.
  • HIV patients with pre-diabetes showed improved blood glucose outcomes over 48 weeks, suggesting that intensive monitoring may not be necessary in the first six months of treatment.
View Article and Find Full Text PDF

Background The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with HIV (PWH) presenting with accelerated hyperglycemia after a few weeks to months of exposure to DTG. Having demonstrated a low incidence of diabetes mellitus and improving blood glucose trajectories in a cohort of ART naïve Ugandan PWH on DTG, we sought to determine whether the observed improvement in blood glucose did not mask background compensated insulin resistance.

View Article and Find Full Text PDF

Introduction: Diseases addressed by surgical, obstetric, trauma and anaesthesia (SOTA) care are rising globally due to an anticipated rise in the burden of non-communicable diseases and road traffic accidents. Low- and middle-income countries (LMICs) disproportionately bear the brunt. Evidence-based policies and political commitment are required to reverse this trend.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiometabolic diseases significantly contribute to health issues in people living with HIV (PWH), yet screening is often neglected in countries like Uganda.
  • A study involving 309 ART-naïve Ugandan adults with HIV found a 13.9% prevalence of metabolic syndrome (MetS), with dyslipidemia being the most common issue.
  • Risk factors for MetS included being over 40 years old and having a CD4 count greater than 200 cells/mm, indicating the need for better monitoring and management of these conditions in similar regions.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate the risk of developing Type 2 Diabetes Mellitus (T2DM) in ART-naïve Ugandan individuals living with HIV after starting dolutegravir (DTG) treatment for 48 weeks.
  • Among 243 participants, the incidence of T2DM was low, with only 1 case reported, while there was a significant occurrence of pre-diabetes (54 cases). Blood glucose levels showed notable changes, indicating fluctuations independent of traditional T2DM risk factors.
  • The findings suggest that, despite concerns, initiating DTG treatment in this population may not substantially increase T2DM risk within the first year, though monitoring is still advised for those with risk factors.
View Article and Find Full Text PDF

Whether integrase strand transfer inhibitors (INSTIs) are associated with a higher risk of incident type 2 diabetes mellitus (DM) than other antiretroviral therapies (ART) needs to be established.MEDLINE, Embase, Web of Science, and ClinicalTrials.gov registries were searched for studies published between 1 January 2000 and 15 June 2022.

View Article and Find Full Text PDF

Background Both pulmonary tuberculosis (PTB) and chronic pulmonary aspergillosis (CPA) significantly affect health-related quality of life (HR-QoL). We aimed to determine the impact of CPA co-infection on the HR-QoL of Ugandans with PTB. Methods We conducted a prospective study among participants with PTB with persistent pulmonary symptoms after 2 months of anti-TB treatment at Mulago Hospital, Kampala, Uganda between July 2020 and June 2021.

View Article and Find Full Text PDF

Background: Over 90% of new paediatric HIV infections are acquired through mother to child transmission. Prevention of mother to child HIV transmission (PMTCT) research in sub-Saharan Africa informed WHO guidelines which enabled implementation of PMTCT programs globally.

Objectives: To describe Makerere University-Johns Hopkins University (MU-JHU) perinatal HIV prevention research and implementation of the Mulago National Referral Hospital (MNRH) PMTCT program.

View Article and Find Full Text PDF

Introduction: In Kampala Uganda, female sex workers (FSWs) have high HIV prevalence (33%). Oral PrEP is a novel HIV prevention intervention that offers hope to decrease HIV incidence in key populations especially among FSWs. Studies have shown that with poor adherence, oral PrEP has no efficacy, and therefore adherence to PrEP is critical among FSWs to maximize HIV prevention.

View Article and Find Full Text PDF

Fetal macrosomia can present with numerous complications. We report a case of a term baby girl with a birthweight of 5.31 kg admitted with respiratory distress and suffered several complications of macrosomia.

View Article and Find Full Text PDF

Optimizing Highly Infectious Disease Isolation Unit Management: Experiences From the Infectious Diseases Isolation and Research Unit, Fort Portal, Uganda.

Disaster Med Public Health Prep

November 2021

Henry M. Jackson Foundation for the Advancement of Military Medicine Inc, Bethesda, Maryland, USA.

Infectious disease outbreaks on the scale of the current coronavirus disease 2019 (COVID-19) pandemic are a new phenomenon in many parts of the world. Many isolation unit designs with corresponding workflow dynamics and personal protective equipment postures have been proposed for each emerging disease at the health facility level, depending on the mode of transmission. However, personnel and resource management at the isolation units for a resilient response will vary by human resource capacity, reporting requirements, and practice setting.

View Article and Find Full Text PDF

Background: Antimicrobial drug resistance is one of the top ten threats to global health according to the World Health Organization. Urinary tract infections (UTIs) are among the most common bacterial infections and main reason for antibiotic prescription. The incidence of UTIs appears to be high among people living with HIV.

View Article and Find Full Text PDF
Article Synopsis
  • HIV significantly increases the risk of tuberculosis (TB), and Isoniazid preventive therapy (IPT) is recommended to help prevent TB reactivation in HIV-positive patients, though it can lead to adverse drug reactions (ADRs).
  • A study conducted in Uganda with 660 HIV-positive patients found a high prevalence of suspected IPT-linked ADRs at 51%, with patients reporting more reactions than recorded in medical files.
  • The most common suspected ADRs included musculoskeletal symptoms, dizziness, and neuropathy, and various factors such as gender, education level, and adherence to IPT were associated with the occurrence of these reactions.
View Article and Find Full Text PDF

Background: We aimed to determine how emerging evidence over the past decade informed how Ugandan HIV clinicians prescribed protease inhibitors (PIs) in HIV patients on rifampicin-based tuberculosis (TB) treatment and how this affected HIV treatment outcomes.

Methods: We reviewed clinical records of HIV patients aged 13 years and above, treated with rifampicin-based TB treatment while on PIs between1st-January -2013 and 30th-September-2018 from twelve public HIV clinics in Uganda. Appropriate PI prescription during rifampicin-based TB treatment was defined as; prescribing doubled dose lopinavir/ritonavir- (LPV/r 800/200 mg twice daily) and inappropriate PI prescription as prescribing standard dose LPV/r or atazanavir/ritonavir (ATV/r).

View Article and Find Full Text PDF

Background: Treatment with effective antiretroviral therapy (ART) lowers morbidity and mortality among HIV positive individuals. Effective highly active antiretroviral therapy (HAART) should lead to undetectable viral load within 6 months of initiation of therapy. Failure to achieve and maintain viral suppression may lead to development of resistance and increase the risk of viral transmission.

View Article and Find Full Text PDF

Background: Cryptococcal infection is a common opportunistic infection among severely immunosuppressed HIV patients and is associated with high mortality. Positive cryptococcal antigenemia is an independent predictor of cryptococcal meningitis and death in patients with severe immunosuppression. We evaluated the prevalence and factors associated with cryptococcal antigenemia among patients with CD4 counts of 100 cells/mm(3) or less in Mulago Hospital, Kampala, Uganda.

View Article and Find Full Text PDF

Background: We aimed to compare the steady-state pharmacokinetic parameters and tolerability of Triomune 40 (stavudine 40 mg, lamivudine 150 mg and nevirapine 200 mg) and branded formulations of these drugs in HIV-infected Ugandans.

Methods: This includes a randomized, open-label, cross-over study of HIV-infected patients stable on therapy for 1 month. Patients were randomized to generic or branded formulation.

View Article and Find Full Text PDF